Business brief
Corporate Truces, Liquidity Crunches, and Aerospace Backlogs
Gold mining giants settle a $2 billion dispute, biotechs execute strategic licensing, private equity faces exit logjams, and regional aerospace backlogs hit records.
Business
Barrick and Newmont ended their rift to unlock a $2 billion expansion — clearing the final legal obstacle for a major North American gold IPO.
BackgroundNevada Gold Mines is a joint complex established in 2019 to combine operations across several major North American deposits. Tensions mounted as Newmont disputed Barrick's rights to exclude surrounding high-grade assets from their shared venture.
- Newmont will pay Barrick $1.95 billion within 30 days to integrate previously excluded properties into the joint complex, streamlining combined mining operations.
- The expanded complex consolidates nearly 100 million ounces of proven gold reserves under one operating structure, creating a single dominant North American mining asset.
- Newmont granted formal approval for Barrick's planned spin-off IPO of its North American assets, paving the way for a public listing in late 2026.
Business
A record backlog of unsold companies and rising debt defaults are freezing private equity returns — forcing buyout firms to hunt for retail cash.
BackgroundPrivate equity relies on IPOs and corporate sales to return capital to institutional investors like pension funds. High interest rates choked off dealmaking, creating a massive logjam of unliquidated assets across private market portfolios.
- Direct lending funds managed by top credit managers saw nonperforming loans rise, pushing sector default rates to a five-year peak of 6%.
- Sluggish payouts to pension funds constrained new institutional fundraising, forcing private equity firms to pitch non-traded funds to retail investors.
- Secondary market trading and continuation funds reached record volumes as private equity managers searched for alternative liquidity solutions.
Business
Sobi is acquiring global rights to Innate's lymphoma antibody — funding Phase 3 trials without forcing the biotech into dilutive stock sales.
BackgroundLacutamab is a first-in-class antibody treatment developed for cutaneous T-cell lymphoma, a rare blood cancer. Biotech firms frequently partner with established rare-disease specialists to fund late-stage clinical trials and global commercial launches.
- Sobi will pay $75 million cash upfront plus up to $505 million in future milestone fees, alongside double-digit royalties on commercial sales.
- Innate will continue executing the ongoing Phase 3 trial to support accelerated regulatory approval applications for rare skin cancer indications.
- The upfront funding extends Innate Pharma's cash runway into late 2027, eliminating immediate dilution risks while giving Sobi full global sales rights.
Business
Embraer is capitalizing on production troubles at larger rivals — building a record $34.5 billion backlog as regional jet demand expands.
BackgroundSupply chain bottlenecks and engine shortages disrupted commercial aircraft manufacturing at Boeing and Airbus. Embraer captured regional market share as airlines and charter operators sought reliable delivery schedules.
- Quarterly deliveries reached 20 commercial aircraft and 45 executive jets, marking a 7% year-over-year volume increase despite industry supply chain headwinds.
- Adjusted EBIT margins reached 10.6% after excluding extraordinary tax credits and tariff impacts, demonstrating strong core operational profitability.
- Company leadership reaffirmed full-year delivery targets across its commercial and defense divisions, signaling confidence in component supply stability.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
